Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean

Bone Marrow Transplantation volume 51, pages 348–350 (2016)Cite this article

Subjects

In this month’s issue, Silvennoinen et al.1 reported the results of a randomized study comparing two different policies for hematopoietic progenitor cell (HPC) mobilization in multiple myeloma (MM) patients.

Autologous stem cell transplantation (ASCT) is a well-established treatment for patients with MM,2 with more than 9500 procedures performed in 2013.3 G-CSF-mobilized HPCs have largely replaced bone marrow as a stem cell source for ASCT, and the engraftment kinetics are mainly dependent on the dose of CD34+ cells infused. The optimal CD34+ cell dose for rapid and sustained recovery in ASCT is generally accepted to be more than 5 × 106/kg, while 2 × 106 CD34+ cells/kg is accepted as the minimum threshold.4 However, target dose should be program-tailored, as in the case of tandem ASCT, in which the suggested minimum target is 6 × 106 CD34+/kg.5

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Silvennoinen R, Anttila P, Säily M, Lundan T, Heiskanen J, Siitonen TM et al. A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma. Bone Marrow Transplant, (e-pub ahead of print 5 October 2015; doi:10.1038/bmt.2015.236).

  2. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014; 371: 895–905.

    Article  Google Scholar 

  3. Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant 2015; 50: 476–482.

    Article  CAS  Google Scholar 

  4. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.

    CAS  Google Scholar 

  5. Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014; 20: 295–308.

    Article  Google Scholar 

  6. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619–625.

    Article  CAS  Google Scholar 

  7. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47: 342–351.

    Article  CAS  Google Scholar 

  8. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  Google Scholar 

  9. Russell N, Douglas K, Ho AD, Mohty M, Carlson K, Ossenkoppele GJ et al. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial. Haematologica 2013; 98: 172–178.

    Article  CAS  Google Scholar 

  10. Danylesko I, Sareli R, Varda-Bloom N, Yerushalmi R, Shem-Tov N, Shimoni A et al. Plerixafor (mozobil): a stem cell-mobilizing agent for transplantation in lymphoma patients predicted to be poor mobilizers – a pilot study. Acta Haematol 2015; 135: 29–36.

    Article  Google Scholar 

  11. Saraceni F, Shem-Tov N, Olivieri A, Nagler A . Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant 2015; 50: 886–891.

    Article  CAS  Google Scholar 

  12. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718–723.

    Article  Google Scholar 

  13. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 795–798.

    Article  CAS  Google Scholar 

  14. Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 874–885.

    Article  CAS  Google Scholar 

  15. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi T-T, Mahlamäki E, Remes K . Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–351.

    Article  CAS  Google Scholar 

  16. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman SR, Rajkumar SV et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood 2006; 107: 3384–3388.

    Article  CAS  Google Scholar 

  17. Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007; 92: 1083–1090.

    Article  Google Scholar 

  18. Attolico I, Nuccorini R, Pizzuti M, Specchia G, Fragasso A, Pavone V et al. Bortezomib-based PBSC mobilization, followed by ASCT, in 75 Multiple Myeloma elderly patients: a prospective multicenter study. Abstract 1672. Bone Marrow Transplant 2015; 50: S1–S96.

    Google Scholar 

  19. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC et al. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant 2015; 50: 1513–1518.

    Article  CAS  Google Scholar 

  20. Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res 2014; 20: 469–479.

    Article  CAS  Google Scholar 

  21. Olivieri J, Pierelli L, Introna M, Accorsi P, Bosi A, Perseghin P et al. Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. Cytotherapy 2014; 16: 101–110.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Bone Marrow Transplantation, Ospedali Riuniti, Ancona, Italy

    A Olivieri & F Saraceni

Authors
  1. A Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Saraceni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Olivieri.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olivieri, A., Saraceni, F. Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean. Bone Marrow Transplant 51, 348–350 (2016). https://doi.org/10.1038/bmt.2015.317

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.317

This article is cited by

Search

Advanced search

Quick links